Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2003-06-18 Capital/Financing Update
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce major events. The text specifically mentions the completion of a public offering of common stock, including details on the number of shares and gross proceeds. This is an update on the company's financing activities. The document is short (2002 characters) and includes a press release as an exhibit. The content fits the category of Capital/Financing Update (CAP) because it reports on a fundraising event (public offering).
2003-06-18 English
PROSPECTUS SUPPLEMENT DATED JUNE 13, 2003
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement dated June 13, 2003, filed pursuant to Rule 424(b)(5) with the SEC. It details an offering of 7,777,778 shares of common stock by Targeted Genetics Corporation, including pricing, risk factors, use of proceeds, and other offering details. The document is a formal disclosure related to a capital raising event, specifically a stock offering. It is not a financial report, earnings release, or management discussion, but rather a detailed capital/financing update describing the terms and risks of the stock issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing.
2003-06-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 13, 2003, by Targeted Genetics Corporation. It announces a public offering of common stock shares, detailing the number of shares, price, gross proceeds, and placement agent information. The content focuses on financing activity and includes references to agreements related to the offering. The document length is 2653 characters, which is relatively short and primarily serves as an announcement of a financing event rather than a detailed financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2003-06-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 5, 2003. It announces preclinical data and clinical trial results presented at a scientific meeting, with press releases attached as exhibits. The content is primarily announcements of events and press releases rather than detailed financial data or comprehensive reports. The document length is 2796 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no detailed financial statement or management discussion present. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2003-06-10 English
FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2003
Interim / Quarterly Report Q1 2003
2003-05-15 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 6, 2003. It includes a press release announcing financial results for the quarter ended March 31, 2003, attached as Exhibit 99.1. The text states that the press release is incorporated by reference and is the main content of the filing. The document length is 2058 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the full financial report itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The presence of a press release announcing quarterly results fits the ER category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2003-05-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.